BioLargo (BLGO) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document Information [Line Items]
Entity Registrant Name	BIOLARGO, INC.
Entity Central Index Key	0000880242
Trading Symbol	blgo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		144,953,058
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 512,000	$ 655,000
Accounts receivable	210,000	257,000
Inventories, net of allowance	26,000	26,000
Prepaid expenses and other current assets	34,000	17,000
Total current assets	782,000	955,000
In-process research and development (Note 8)	1,893,000	1,893,000
Equipment, net of depreciation	110,000	126,000
Other non-current assets	35,000	35,000
Right-of-use, operating lease, net of amortization	399,000
Deferred offering cost	176,000	176,000
Total assets	3,395,000	3,185,000
Current liabilities:
Accounts payable and accrued expenses	631,000	501,000
Notes payable	490,000	400,000
Line of credit	430,000	430,000
Convertible notes payable	2,072,000	1,365,000
Discount on convertible notes payable, and line of credit, net of amortization	(646,000)	(205,000)
Lease liability	116,000
Customer deposit	32,000
Total current liabilities	3,125,000	2,491,000
Long-term liabilities:
Convertible notes and note payable	235,000	285,000
Clyra Medical note payable (Note 8)	1,242,000	1,292,000
Discount on convertible notes payable, net of amortization	(105,000)	(118,000)
Lease liability	283,000
Total long-term liabilities	2,063,000	1,817,000
Total liabilities	5,188,000	4,308,000
COMMITMENTS, CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2018 and March 31, 2019, respectively.
Common stock, $.00067 Par Value, 400,000,000 Shares Authorized, 141,466,071 and 144,473,453 Shares Issued, at December 31, 2018 and March 31, 2019, respectively.	97,000	95,000
Additional paid-in capital	112,556,000	110,222,000
Accumulated other comprehensive loss	(94,000)	(90,000)
Accumulated deficit	(114,641,000)	(111,723,000)
Total BioLargo Inc. and Subsidiaries stockholders’ equity (deficit)	(2,082,000)	(1,496,000)
Non-controlling interest (Note 8)	289,000	373,000
Total stockholders’ equity (deficit)	(1,793,000)	(1,123,000)
Total liabilities and stockholders’ equity (deficit)	3,395,000	3,185,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 8)	643,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term liabilities:
Clyra Medical note payable (Note 8)	1,007,000	$ 1,007,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member] | Scion Acquisition [Member]
Long-term liabilities:
Clyra Medical note payable (Note 8)	$ 1,007,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Common Stock, Shares Authorized (in shares)	400,000,000	400,000,000
Common Stock, Shares Issued (in shares)	144,473,453	141,466,071

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Revenue	$ 364,000	$ 364,000
Cost of revenue
Cost of Goods and Services Sold	(192,000)	(163,000)
Gross profit	172,000	100,000
Operating expenses:
Selling, general and administrative expenses	1,392,000	1,170,000
Research and development	426,000	522,000
Depreciation and amortization	16,000	10,000
Total operating expenses	1,834,000	1,702,000
Operating loss	(1,662,000)	(1,602,000)
Grant income	82,000	5,000
Interest expense	(985,000)	(832,000)
Gain (Loss) on Extinguishment of Debt, Total	(184,000)
Total other (expense) income	(1,087,000)	(827,000)
Net loss	(2,749,000)	(2,429,000)
Net loss attributable to noncontrolling interest	(173,000)	(107,000)
Net loss attributable to common shareholders	$ (2,576,000)	$ (2,322,000)
Net loss per share attributable to common stockholders:
Loss per share attributable to shareholders – basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)
Weighted average number of common shares outstanding: (in shares)	142,246,766	104,695,818
Comprehensive loss attributable to common shareholders
Net loss	$ (2,749,000)	$ (2,429,000)
Foreign translation adjustment	(4,000)	8,000
Comprehensive loss	(2,753,000)	(2,421,000)
Comprehensive loss attributable to noncontrolling interest	(1,793,000)	(107,000)
Comprehensive loss attributable to shareholders	(2,580,000)	(2,314,000)
Product [Member]
Revenue:
Revenue	301,000	224,000
Cost of revenue
Cost of Goods and Services Sold	(140,000)	(134,000)
Service [Member]
Revenue:
Revenue	63,000	39,000
Cost of revenue
Cost of Goods and Services Sold	$ (52,000)	$ (29,000)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Stock Issued for Financing Fee [Member]Common Stock [Member]	Stock Issued for Financing Fee [Member]Additional Paid-in Capital [Member]	Stock Issued for Financing Fee [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]Additional Paid-in Capital [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017						104,164,465
Balance at Dec. 31, 2017						$ 70,000	$ 97,093,000	$ (101,205,000)	$ (62,000)	$ 695,000	$ (3,409,000)
Issuance of common stock for service (in shares)						714,436
Issuance of common stock for service						$ 1,000	196,000				197,000
Issuance of common stock for interest (in shares)						617,072
Issuance of common stock for interest							165,000				165,000
Financing fee in stock (in shares)	252,385
Financing fee in stock		$ 85,000	$ 85,000
Sale of stock for cash (in shares)						658,226
Sale of stock for cash							168,000				168,000
Stock option compensation expense							320,000				320,000
Warrants and conversion feature issued as discount on convertible notes payable							282,000				282,000
Deemed dividend for the change in accounting for derivative liability							297,000	(297,000)
Net loss								(2,323,000)		(107,000)	(2,429,000)
Foreign currency translation									8,000		8,000
Balance (in shares) at Mar. 31, 2018						106,406,584
Balance at Mar. 31, 2018						$ 71,000	98,606,000	(103,825,000)	(54,000)	588,000	(4,614,000)
Balance (in shares) at Dec. 31, 2018						141,466,071
Balance at Dec. 31, 2018						$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Issuance of common stock for service (in shares)						1,229,541
Issuance of common stock for service						$ 1,000	205,000				206,000
Issuance of common stock for interest (in shares)						139,362
Issuance of common stock for interest							25,000				25,000
Stock option compensation expense							352,000				352,000
Warrants and conversion feature issued as discount on convertible notes payable				$ 56,000	$ 56,000		1,115,000				1,115,000
Deemed dividend for the change in accounting for derivative liability							342,000	(342,000)
Net loss								(2,576,000)		(173,000)	(2,749,000)
Foreign currency translation									(4,000)		(4,000)
Balance (in shares) at Mar. 31, 2019						144,473,453
Balance at Mar. 31, 2019						$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Conversion of notes (in shares)						1,638,479
Conversion of notes						$ 1,000	218,000				219,000
Issuance of Clyra Medical common stock							$ 21,000			$ 89,000	$ 110,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net loss	$ (2,749,000)	$ (2,429,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	352,000	320,000
Common stock issued in lieu of salary to officers and fees for services from vendors	206,000	196,000
Common stock issued for interest	25,000	165,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	851,000	635,000
Interest expense related to the fair value of warrants issued as consent for variable debt	54,000
Loss on extinguishment of debt	184,000
Deferred offering expense		4,000
Amortization and depreciation expense	16,000	10,000
Changes in assets and liabilities:
Accounts receivable	47,000	(8,000)
Inventories		(3,000)
Accounts payable and accrued expenses	129,000	127,000
Prepaid expenses and other current assets	(16,000)	(13,000)
Customer deposits	32,000
Net cash used in operating activities	(869,000)	(996,000)
Cash flows from investing activities
Equipment purchases		(19,000)
Net cash used in investing activities		(19,000)
Cash flows from financing activities
Proceeds from convertible notes payable	750,000	380,000
Proceeds from the sale of stock in Clyra Medical	110,000
Repayment of note payable	(300,000)
Proceeds from sale of stock to Lincoln Park Capital		168,000
Proceeds from notes payable	170,000
Proceeds from line of credit		390,000
Net cash provided by financing activities	730,000	938,000
Net effect of foreign currency translation	(4,000)	8,000
Net change in cash	(143,000)	(69,000)
Cash at beginning of year	655,000	990,000
Cash at end of period	512,000	921,000
Supplemental disclosures of cash flow information
Interest	32,000
Income taxes	3,000
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes	1,061,000	282,000
Right of use, operating lease and liability	399,000
Deemed dividend	342,000	297,000
Conversion of Convertible Notes Payable into Common Stock [Member]
Non-cash investing and financing activities
Conversion of debt	220,000
Conversion of Convertible Notes Issued with Original Issue Discount [Member]
Non-cash investing and financing activities
Conversion of debt	217,000
Stock Issued for Financing Fee [Member]
Non-cash investing and financing activities
Fair value of stock issued		$ 85,000

Note 1 - Business and Organizat

Note 1 - Business and Organization	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business BioLargo, Inc. delivers innovative and sustainable technology-based products and services, as well as environmental engineering expertise, across a broad range of industries with an overriding mission to “make life better” with a focus on clean water, clean air, and advanced wound care. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. For the three March 31, 2019, $2,749,000, $869,000 March 31, 2019, $2,343,000, $782,000. not December 31, 2019, December 31, 2018, three March 31, 2019, $1,364,000 $364,000 two No 10, 12 4 $2,072,000 $440,000 June 6, 2019, may September 2019, $430,000 September 1, 2019. 2019, three March 31, 2019, $730,000 March 31, 2019 $512,000. No The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract significant new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technologies. The consolidated financial statements do not Organization We are a Delaware corporation formed in 1991. five 2006; No 2009; 2014; 2016; 2017 42.0% 2012, 2 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not three March 31, 2019 not may December 31, 2019, 10 December 31, 2018 March 29, 2019,

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. In the opinion of management, the accompanying balance sheet and related statements of operations, cash flows, and stockholders’ deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and Clyra Medical. Management believes Clyra Medical’s financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810, not 42% All intercompany accounts and transactions have been eliminated (see Note 8 Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2018 March 31, 2019, December 31, 2018 March 31, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 193 $ 183 Clyra Medical Technologies, Inc. 462 329 Total $ 655 $ 512 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2018 March 31, 2019 Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three March 31, 2018 2019, three 10% March 31, 201 8 March 31, 201 9 Customer A 39 % 43 % Customer B 18 % 10 % Customer C <10 % 26 % Customer D 18 % <10 % We had two 10% December 31, 2018 March 31, 2019 December 31, 201 8 March 31, 201 9 Customer X 12 % 25 % Customer Y 31 % <10 % Customer Z <10 % 11 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2018 March 31, 2019 $3,000. December 31, 2018 March 31, 2019, December 31, 201 8 March 31, 201 9 Raw material $ 14 $ 14 Finished goods 12 12 Total $ 26 $ 26 Other Assets Other Assets consisted of security deposits of $35,000 Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2018 March 31, 2019, no Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three March 31, 2018 2019, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis for employees over the applicable service period of the award, which is the vesting period. We recognize compensation expense for stock option awards for non-employees at the fair value on the grant date. Generally, the options issued to non-employees have been earned upon issuance. For the instances that options are issued to non-employees with a vesting schedule, the fair value is recorded on each vesting date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three March 31, 2018 2019: 2018 2019 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.43 % n/a 2.65 % 2.65 % Expected volatility 252 % n/a 152 % 152 % Expected dividend yield — n/a — — Forfeiture rate — n/a — — Life in years 7 n/a 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. As present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We adopted ASU 2014 09, 606, January 1, 2018. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from two No No No No BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST’s contracts typically call for invoicing for time and materials incurred for that contract. To date, there have been no In the future, we may one Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations. We received our first 2015 60 $3.6 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of December 31, 2018 March 31, 2019 Tax Credits Our research and development activities in Canada may not Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 820, December 15, 2019, not not In June 2018, No. 2018 07, 718 718 718 718 718 not 1 2 606, December 15, 2018, not In February 2016, No. 2016 02, January 1, 2019 July 2018. $399,000 may

Note 3 - Lincoln Park Financing

Note 3 - Lincoln Park Financing	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3. On August 25, 2017, $10 three may three 12 no first may not We did not three March 31, 2019. three March 31, 2018, 650,000 $168,220. 8,226 We record stock sales in our equity statement and the additional commitment shares issued reduce the deferred offering costs on our balance sheet.

Note 4 - Debt Obligations

Note 4 - Debt Obligations	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. The following table summarizes our debt obligations outstanding as of December 31, 2018 March 31, 2019 ( December 31, 201 8 March 31, 201 9 C urrent liabilities: Notes payable, mature June 6, 2019 $ 400 $ 440 Note payable, matures on demand 60 days’ notice (or March 8, 2023) — 50 Line of credit, matures September 1, 2019 or later (on 30-day demand) 430 430 Convertible notes payable: Convertible notes, mature December 31, 2019 ( 1 ) 75 75 Convertible note, matured January 11, 2019 300 — Convertible note, matures July 15, 2019 550 420 Convertible note, matures July 20, 2019 ( 1 ) 440 440 Convertible note, matures October 7, 2019 — 370 Convertible note, matures November 5, 2019 and December 7, 2019 — 554 Convertible nine-month notes, due October, November 2019 — 213 Total convertible notes payable $ 1,365 $ 2,072 Total current liabilities $ 2,195 $ 2,992 L ong-term liabilities : Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (See Note 8) 1,007 1,007 Convertible notes payable, mature June 20, 2020 (1) 25 25 Convertible notes payable, mature April 20, 2021 (1) 100 100 Convertible notes, mature June 15, 2021 (1) 110 110 Note payable, matures March 8, 2023 (or on demand 60 days’ notice) 50 — Total long-term liabilities $ 1,292 $ 1,242 Total $ 3,487 $ 4,234 ( 1 ) For the three March 31, 2018 2019 $832,000 $985,000 The following discussion includes debt instruments to which amendments were made or included other activity that management deemed appropriate to disclose. Each of the debt instruments contained in the above table are disclosed more fully in the financial statements contained in the Company’s Annual Report filed March 29, 2019, Notes payable, mature June 6, 2019 On September 19, 2018, $400,000 January 5, 2019 12%, 6 two first $280,000, second $120,000 January 3, 2019, two $400,000 60 March 6, 2019. 10%, two $440,000 January 5, 2019. On March 5, 2019, two June 6, 2019, may September 6, 2019 10%. March 5, 2019 12% 18%, March 7, 2019, two Convertible note payable, matures January 11, 2019 ( On October 16, 2018, $225,000 $300,000 5%, January 11, 2019. $75,000 three March 31, 2019. On January 8, 2019, Convertible Note, matures July 15, 2019 ( On January 7, 2019, December 14, 2017 ( 2017 April 15, 2019. $605,100. five 80% 25 20% 15%, 15% 30% 25% $487,000, three March 31, 2019. On March 28, 2019, 2017 July 15, 2019. 10 $420,000. $38,000 three March 31, 2019. During the three March 31, 2019, $225,000 2017 1,679,248 1,638,479 40,769 March 31, 2019, $420,000. Convertible Note, matures October 7, 2019 ( On January 7, 2019, $300,000 2019 $330,000, nine October 7, 2019). 2019 one 12%, 2019 65% 25 2019 4.99% may 2019 90 10 120% 10 2019 2019 not November 6, 2018). $300,000, 2019. With respect to the above transactions with Vista Capital, Lincoln Park Capital Fund, LLC agreed to waive the provisions of the Purchase Agreement dated August 25, 2017, 250,000 $0.25 five not 6 Convertible Notes, due November 5, 2019 December 7, 2019 ( On January 31, 2019, 12% $495,000 two nine 12% $300,000 February 5, 2019, $330,000 10% November 5, 2019. second $150,000, March 7, 2019, $495,000. second December 7, 2019. $554,000. The Tangiers Note is convertible at the option of Tangiers at a conversion price equal to 75% 25 $185,000, 2019. We may 180 90 25%; 91 180 30%. may not 144 10 six may 22% 25% In connection with the Tangiers Note, the Company caused its transfer agent to reserve 3,000,000 With respect to the above transaction with Tangiers, Lincoln Park consented to waive the provisions of the Purchase Agreement dated August 25, 2017 50,000 $0.25 five not 6 Nine-month Notes payable During the three March 31, 2019, $212,500, 25% $0.25 nine January 14, 2019, $50,000 $62,500. January 22, 2019, $20,000 $25,000. February 4, 2019, $100,000 $125,000. $42,500, Each OID Note is convertible by the investor at any time at $0.25 $0.25. five 5% may 10 may The Company must prepay the OID Notes upon the conclusion of a “qualifying offering” (an offering raising $3.5 not not seventy 70% 25 In addition to the note, each OID investor will receive a warrant to purchase common stock for $0.25 5 75% $0.25 $100,000 $125,000, 375,000 not not 6

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries On March 29, 2019, 579,996 $0.16 $93,000 On March 31, 2018, 323,030 $0.26 $84,000 Payment of Consultant Fees and Accrued Interest During the three March 31, 2019, 788,907 $0.16 $0.23 $138,000 During the three March 31, 2018, 1,008,478 $0.25 $0.41 $277,000 Stock Option Expense During the three March 31, 2018 2019, $320,000 $352,000, 2018 2007 2018 On June 22, 2018, 2018 “2018 may 10 2018 40 2018 January 1 st 2 Activity for our stock options under the 2018 December 31, 2018, March 31, 2019, 2018 June 2018, no March 31, 2018). Weighted Average Aggregate Options Exercise Price per intrinsic As of March 31, 2019 : Outstanding Price per share share Value (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 890,280 0.16 – 0.22 0.19 Expired — — — Balance, March 31, 2019 2,208,797 $0.16 – 0.43 $ 0.25 $ — ( 1 $0.16 March 31, 2019. The options to purchase 890,280 three March 31, 2019 300,000 $0.22 168,404 $0.16 $0.25 $36,000 421,876 $0.16 $68,000 Chief Financial Officer Contract Extension On January 16, 2019, February 1, 2008 ( January 16, 2019 ( September 30, 2019 ( September 30, 2018. December 31, 2018 For the Extended Term, Mr. Dargan was issued an option (“Option”) to purchase 300,000 January 16, 2019 $0.22, January 16, 2029, 75,000 March 31, 2019, 25,000 January 31, 2019, 2018 $67,000, $17,000 three March 31, 2019. The issuance of the Option is Mr. Dargan’s sole source of compensation for the Extended Term. As was the case in all prior terms of his engagement, there is no no not 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may 10 September 7, 2017. September 2017, Activity for our stock options under the 2007 three March 31, 2018 2019 Weighted Average Aggregate Options Exercise Price per intrinsic As of March 31, 2018 : Outstanding p rice per share share Value (1) Balance, December 31, 2017 9,831,586 $0.23 – 1.89 $ 0.44 Expired (50,000 ) 1.89 0.91 Balance, March 31, 2018 9,781,586 $0.23 – 1.65 $ 0.43 $ — As of March 31, 2019 : Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (30,000 ) 0.38 – 0.70 0.50 Balance, March 31, 2019 9,661,586 $0.23 – 1.65 $ 0.43 $ — ( 1 $0.16 March 31, 2019. Non-Plan Options issued During the three March 31, 2019, 731,250 $0.16 $0.25 $139,000, During the three March 31, 2018, 619,435 $0.26 $0.28 $158,000. Activity of our non-plan stock options issued for the three March 31, 2018 2019 Weighted Non-plan a verage Aggregate Options Exercise p rice per intrinsic As of March 31, 2018 : o utstanding p rice per share share value (1) Balance, December 31, 2017 20,018,408 $0.25 – 1.00 $ 0.51 Granted 619,435 0.26 – 0.28 0.26 Expired (2,400,000 ) 0.99 0.99 Balance, March 31, 2018 18,237,843 $0.25 – 1.00 $ 0.45 $ — As of March 31, 2019 : Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 731,250 0.16 – 0.25 0.19 Balance, March 31, 2019 20,050,746 $0.25 – 1.00 $ 0.42 $ — ( 1 $0.16 March 31, 2019.

Note 6 - Warrants

Note 6 - Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Warrants [Text Block]	Note 6. We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Weighted a verage Aggregate Warrants Exercise p rice per intrinsic As of March 31, 2018 : o utstanding p rice per share share value (1) Balance, December 31, 2017 22,104,817 $0.125 – 1.00 $ 0.45 Issued 2,611,513 0.25 – 0.48 0.35 Balance, March 31, 2018 24,716,330 $0.125 – 1.00 $ 0.44 $ — As of March 31, 2019 : Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 3,861,041 $0.16 – 0.25 $ 0.24 Balance, March 31, 2019 30,733,471 $0.20 – 1.00 $ 0.40 $ — Warrants issued as part of debt extension On March 5, 2019, June 6, 2019 ( 4 1,387,500 $0.25 September 19, 2023. $0.20 1,734,375. $346,875 600,000 750,000 $0.20 $56,000 three March 31, 2019. Warrants issued as consent for variable rate debt On January 7 January 31, 2019, August 25, 2017, 300,000 $0.25 five not $54,000 2019 4 Warrants Issued concurrently with the Nine-month note payable Pursuant to the terms of the OID Offering, in addition to the Note, the investor will receive a warrant to purchase common stock for $0.25 5 75% $0.25 $100,000 $125,000, 375,000 637,500 not not $89,000 2019 4 Warrants Issued to One-Year Noteholders In conjunction with three one three 400,000 two July 8, 2016 ( 400,000 $0.65 December 30, 2016 ( 400,000 $0.75 Each of these warrants contained provisions that required a reduction to the exercise price and increase to the number of warrant shares in the event that we sold our common stock at a lower price than the exercise price (subject to some exceptions). During the three March 31, 2019, three $0.12, 2,426,666 $342,000, Fair Value – Interest Expense To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement management also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: March 31, 2018 March 31, 2019 Risk free interest rate 2.54% 2.18 – 2.62% Expected volatility 252% 86 – 110% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 – 10 2 – 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7. Accounts payable and accrued expenses included the following (in thousands): December 31, 2018 March 31, 2019 Accounts payable and accrued expense $ 302 $ 370 Accrued interest 122 151 Accrued payroll 77 110 Total accounts payable and accrued expenses $ 501 $ 631

Note 8 - Noncontrolling Interes

Note 8 - Noncontrolling Interest - Clyra Medical	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. We consolidate the operations of our partially owned subsidiary Clyra Medical (see Note 2 Acquisition of In-process Research and Development On September 26, 2018, 21,000 10,000 7,142,858 $1,250,000 $1 On December 17, 2018, $1 one 15,500 one fifth $100,000 $100,000 $500,000 $1 $2 Scion Solutions – Note Payable and Clyra Liability The promissory note in the principal amount of $1,250,000 September 26, 2018 ( 5%. 25% not 18 12 18 25% 12 5% Non-Controlling Interest As of March 31, 2019, $1,110,000 $200 three March 31, 2019, $110,000 550 March 31, 2019, $1,007,000. As of March 31, 2019, Shareholder Shares Percent BioLargo, Inc. 28,053 42.0 % Sanatio Capital (1) 11,520 17.4 % Scion Solutions (2) 15,500 23.4 % Other 11,772 17.2 % Total 66,845 Notes: ( 1 9,830 1,690 ( 2 not 15,500 Sanatio Capital purchased Series A Preferred shares in 2015. 8% five no 510 December 20, no March 31, 2019 $200,000. Holders of Preferred Shares are entitled to preferential payments in the event of a liquidation, dissolution or winding up of the company, in an amount equal to any accrued and unpaid dividends. After such preference, any remaining assets are distributed pro-rata between holders of Clyra Medical common stock and Preferred Shares as if the Preferred Shares had converted to Clyra Medical common stock. Holders of Preferred Shares may one one Preferred shares may one one one one

Note 9 - BioLargo Engineering,

Note 9 - BioLargo Engineering, Science and Technologies, LLC	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 9. In September 2017, three seven 10 two 100% no five 30% 2 five March 31, 2018 ( not 90% 10% first September 2018. 8 September 8, 2017. The Compensation Committee met on September 26, 2018 not not one

Note 10 - Business Segment Info

Note 10 - Business Segment Information	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 10. BioLargo currently has four four 1. Odor- No 2. Clyra Medical (“Clyra”) -- which is engaged in developing medical products and preparing launch into commercial activity with approval of its FDA 510 3. BLEST -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed (located in Oak Ridge, Tennessee); 4. BioLargo Water (“Water”) -- which historically focused entirely on R&D, and has now shifted its focus to commercializing the AOS technology (located in Edmonton, Alberta Canada); and Historically, none No third December 31, 2018, No $417,000 $500,000 2017 $1 2018 The segment information for the three March 31, 2018 2019, As of March 31, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ — $ 301 $ — $ 183 $ — $ (120 ) $ 364 Intersegment revenue — — — (120 ) — — — Operating loss (948 ) (90 ) (287 ) (110 ) (227 ) — (1,662 ) Grant income — — — — 82 — 82 Interest expense (632 ) — (12 ) — — — (985 ) Depreciation — (4 ) — (12 ) — — (16 ) Research and development (172 ) — (49 ) (122 ) (209 ) 126 (426 ) Loss on extinguishment (184 ) — — — — — (184 ) Net loss (2,105 ) (90 ) (299 ) (110 ) (145 ) — (2,749 ) As of March 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ — $ 224 $ — $ 189 $ — $ (120 ) $ 364 Intersegment revenue — — — (150 ) — — — Operating loss (1,093 ) (109 ) (199 ) (45 ) (156 ) — (1,602 ) Grant income — — — — 5 — 5 Interest expense (830 ) — — (2 ) — — (832 ) Depreciation — (4 ) — (6 ) — — (10 ) Research and development (343 ) — (87 ) (100 ) (142 ) 150 (522 ) Net loss (1,924 ) (109 ) (199 ) (46 ) (151 ) — (2,429 ) As of March 31, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 673 $ 182 $ 277 $ 329 $ 48 $ (6 ) $ 1,503 Intangible assets 1,893 — — — — — 1,893 As of December 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 353 $ 220 $ 462 $ 230 $ 33 $ (6 ) $ 1,292 Intangible assets 1,893 — — — — — 1,893

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11. Calvert Employment Agreement On May 2, 2017, April 30, 2007. The Calvert Employment Agreement provides that Mr. Calvert will continue to serve as our President and Chief Executive Officer and receive base compensation equal to his current rate of pay of $289,000 four may Pursuant to the Calvert Employment Agreement, we granted Mr. Calvert a non-qualified stock option (the “Option”) to purchase 3,731,322 $0.45 ten five 6 not 1,500,000 $3 $3 12 The Calvert Employment Agreement has a term of five may 120 360 one one one one The Calvert Employment Agreement requires Mr. Calvert to keep certain information confidential, not Office Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. For the three March 31, 2018 2019, $49,000 $51,000, January 1, 2019, 842 not 4 18%. not The leases have no not Clyra Medical Consulting Agreement Our partially owned subsidiary Clyra Medical (see Note 8 8 $23,000 four not $1.1

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. Management has evaluated subsequent events through the date of the filing of this Annual Report and management noted the following for disclosure. Bellridge Capital Investment On April 18, 2019, $188,000 10% $220,000 10% $10,000 April 18, 2020. may $400,000 two two 10% one The Bellridge Note is convertible at the option of Bellridge at a conversion price equal to 70% 25 may 90 125% 130% 24% Crossover Capital Investment On May 14, 2019, $95,000 $110,000 10% $5,000 nine 70% 25 may 180 5% first 30 30% 30. 24%

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and Clyra Medical. Management believes Clyra Medical’s financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810, not 42% All intercompany accounts and transactions have been eliminated (see Note 8
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2018 March 31, 2019, December 31, 2018 March 31, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 183 $ 183 Clyra Medical Technologies, Inc. 462 329 Total $ 655 $ 512
Receivable [Policy Text Block]	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2018 March 31, 2019 zero
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three March 31, 2018 2019, three 10% March 31, 201 8 March 31, 201 9 Customer A 39 % 43 % Customer B 18 % 10 % Customer C <10 % 26 % Customer D 18 % <10 % We had two 10% December 31, 2018 March 31, 2019 December 31, 201 8 March 31, 201 9 Customer X 12 % 25 % Customer Y 31 % <10 % Customer Z <10 % 11 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2018 March 31, 2019 $3,000 December 31, 2018 March 31, 2019, December 31, 201 8 March 31, 201 9 Raw material $ 14 $ 14 Finished goods 12 12 Total $ 26 $ 26
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Other Assets Other Assets consisted of security deposits of $35,000
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2018 March 31, 2019, no
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three March 31, 2018 2019,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis for employees over the applicable service period of the award, which is the vesting period. We recognize compensation expense for stock option awards for non-employees at the fair value on the grant date. Generally, the options issued to non-employees have been earned upon issuance. For the instances that options are issued to non-employees with a vesting schedule, the fair value is recorded on each vesting date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three March 31, 2018 2019: 2018 2019 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.43 % n/a 2.65 % 2.65 % Expected volatility 252 % n/a 152 % 152 % Expected dividend yield — n/a — — Forfeiture rate — n/a — — Life in years 7 n/a 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. As present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We adopted ASU 2014 09, 606, January 1, 2018. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from two No No No No BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST’s contracts typically call for invoicing for time and materials incurred for that contract. To date, there have been no In the future, we may one
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations. We received our first 2015 60 $3.6 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of December 31, 2018 March 31, 2019
Tax Credits [Policy Text Block]	Tax Credits Our research and development activities in Canada may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 820, December 15, 2019, not not In June 2018, No. 2018 07, 718 718 718 718 718 not 1 2 606, December 15, 2018, not In February 2016, No. 2016 02, January 1, 2019 July 2018. $399,000 may

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	December 31, 2018 March 31, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 193 $ 183 Clyra Medical Technologies, Inc. 462 329 Total $ 655 $ 512
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	March 31, 201 8 March 31, 201 9 Customer A 39 % 43 % Customer B 18 % 10 % Customer C <10 % 26 % Customer D 18 % <10 % December 31, 201 8 March 31, 201 9 Customer X 12 % 25 % Customer Y 31 % <10 % Customer Z <10 % 11 %
Schedule of Inventory, Current [Table Text Block]	December 31, 201 8 March 31, 201 9 Raw material $ 14 $ 14 Finished goods 12 12 Total $ 26 $ 26
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2019 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.43 % n/a 2.65 % 2.65 % Expected volatility 252 % n/a 152 % 152 % Expected dividend yield — n/a — — Forfeiture rate — n/a — — Life in years 7 n/a 7 7

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 201 8 March 31, 201 9 C urrent liabilities: Notes payable, mature June 6, 2019 $ 400 $ 440 Note payable, matures on demand 60 days’ notice (or March 8, 2023) — 50 Line of credit, matures September 1, 2019 or later (on 30-day demand) 430 430 Convertible notes payable: Convertible notes, mature December 31, 2019 ( 1 ) 75 75 Convertible note, matured January 11, 2019 300 — Convertible note, matures July 15, 2019 550 420 Convertible note, matures July 20, 2019 ( 1 ) 440 440 Convertible note, matures October 7, 2019 — 370 Convertible note, matures November 5, 2019 and December 7, 2019 — 554 Convertible nine-month notes, due October, November 2019 — 213 Total convertible notes payable $ 1,365 $ 2,072 Total current liabilities $ 2,195 $ 2,992 L ong-term liabilities : Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (See Note 8) 1,007 1,007 Convertible notes payable, mature June 20, 2020 (1) 25 25 Convertible notes payable, mature April 20, 2021 (1) 100 100 Convertible notes, mature June 15, 2021 (1) 110 110 Note payable, matures March 8, 2023 (or on demand 60 days’ notice) 50 — Total long-term liabilities $ 1,292 $ 1,242 Total $ 3,487 $ 4,234

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Aggregate Options Exercise Price per intrinsic As of March 31, 2019 : Outstanding Price per share share Value (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 890,280 0.16 – 0.22 0.19 Expired — — — Balance, March 31, 2019 2,208,797 $0.16 – 0.43 $ 0.25 $ — Weighted Average Aggregate Options Exercise Price per intrinsic As of March 31, 2018 : Outstanding p rice per share share Value (1) Balance, December 31, 2017 9,831,586 $0.23 – 1.89 $ 0.44 Expired (50,000 ) 1.89 0.91 Balance, March 31, 2018 9,781,586 $0.23 – 1.65 $ 0.43 $ — As of March 31, 2019 : Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (30,000 ) 0.38 – 0.70 0.50 Balance, March 31, 2019 9,661,586 $0.23 – 1.65 $ 0.43 $ — Weighted Non-plan a verage Aggregate Options Exercise p rice per intrinsic As of March 31, 2018 : o utstanding p rice per share share value (1) Balance, December 31, 2017 20,018,408 $0.25 – 1.00 $ 0.51 Granted 619,435 0.26 – 0.28 0.26 Expired (2,400,000 ) 0.99 0.99 Balance, March 31, 2018 18,237,843 $0.25 – 1.00 $ 0.45 $ — As of March 31, 2019 : Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 731,250 0.16 – 0.25 0.19 Balance, March 31, 2019 20,050,746 $0.25 – 1.00 $ 0.42 $ —

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted a verage Aggregate Warrants Exercise p rice per intrinsic As of March 31, 2018 : o utstanding p rice per share share value (1) Balance, December 31, 2017 22,104,817 $0.125 – 1.00 $ 0.45 Issued 2,611,513 0.25 – 0.48 0.35 Balance, March 31, 2018 24,716,330 $0.125 – 1.00 $ 0.44 $ — As of March 31, 2019 : Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 3,861,041 $0.16 – 0.25 $ 0.24 Balance, March 31, 2019 30,733,471 $0.20 – 1.00 $ 0.40 $ —
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	March 31, 2018 March 31, 2019 Risk free interest rate 2.54% 2.18 – 2.62% Expected volatility 252% 86 – 110% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 – 10 2 – 5

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2018 March 31, 2019 Accounts payable and accrued expense $ 302 $ 370 Accrued interest 122 151 Accrued payroll 77 110 Total accounts payable and accrued expenses $ 501 $ 631

Note 8 - Noncontrolling Inter_2

Note 8 - Noncontrolling Interest - Clyra Medical (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Shareholder Shares Percent BioLargo, Inc. 28,053 42.0 % Sanatio Capital (1) 11,520 17.4 % Scion Solutions (2) 15,500 23.4 % Other 11,772 17.2 % Total 66,845

Note 10 - Business Segment In_2

Note 10 - Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	As of March 31, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ — $ 301 $ — $ 183 $ — $ (120 ) $ 364 Intersegment revenue — — — (120 ) — — — Operating loss (948 ) (90 ) (287 ) (110 ) (227 ) — (1,662 ) Grant income — — — — 82 — 82 Interest expense (632 ) — (12 ) — — — (985 ) Depreciation — (4 ) — (12 ) — — (16 ) Research and development (172 ) — (49 ) (122 ) (209 ) 126 (426 ) Loss on extinguishment (184 ) — — — — — (184 ) Net loss (2,105 ) (90 ) (299 ) (110 ) (145 ) — (2,749 ) As of March 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Revenue $ — $ 224 $ — $ 189 $ — $ (120 ) $ 364 Intersegment revenue — — — (150 ) — — — Operating loss (1,093 ) (109 ) (199 ) (45 ) (156 ) — (1,602 ) Grant income — — — — 5 — 5 Interest expense (830 ) — — (2 ) — — (832 ) Depreciation — (4 ) — (6 ) — — (10 ) Research and development (343 ) — (87 ) (100 ) (142 ) 150 (522 ) Net loss (1,924 ) (109 ) (199 ) (46 ) (151 ) — (2,429 ) As of March 31, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 673 $ 182 $ 277 $ 329 $ 48 $ (6 ) $ 1,503 Intangible assets 1,893 — — — — — 1,893 As of December 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 353 $ 220 $ 462 $ 230 $ 33 $ (6 ) $ 1,292 Intangible assets 1,893 — — — — — 1,893

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)		3 Months Ended		12 Months Ended
		Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (2,749,000)	$ (2,429,000)
Net Cash Provided by (Used in) Operating Activities, Total		(869,000)	(996,000)
Working Capital		2,343,000
Assets, Current, Total		782,000		$ 955,000
Revenue from Contract with Customer, Including Assessed Tax		$ 364,000	364,000	1,364,000
Number of Reportable Segments		2
Convertible Notes Payable, Current		$ 2,072,000		1,365,000
Cash Provided by Financing Activities		730,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 512,000	$ 921,000	655,000	$ 990,000
Number of Wholly-Owned Subsidiaries		5
Clyra Medical Technology Inc [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent		42.00%
Notes Payable, Maturing June 6, 2019 [Member]
Convertible Notes Payable, Current		$ 440,000
Line of Credit, Maturing September 1, 2019 [Member]
Long-term Line of Credit, Total	[1]	430,000		$ 430,000
Convertible Notes Payable [Member]
Short-term Debt, Total		$ 2,072,000
[1]	See Note 14 "Subsequent Events"

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018	Dec. 31, 2018USD ($)
Cash, FDIC Insured Amount	$ 250,000
Inventory Valuation Reserves, Ending Balance	3,000		$ 3,000
Security Deposit	35,000
Impairment of Long-Lived Assets Held-for-use	$ 0		0
Number of Grants Received	60
Operating Lease, Right-of-Use Asset	$ 399,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance	0		0
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset	399,000
Operating Lease, Liability, Total	$ 399,000
Canadian Government Grants [Member]
Grants Receivable			$ 3,600,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term	180 days
Canadian Government Grants [Member] | Maximum [Member]
Grant Term	1 year 180 days
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]
Number of Major Customers		3
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	2
Clyra Medical Technology Inc [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent	42.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 512,000	$ 655,000	$ 921,000	$ 990,000
Parent Company [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance	183,000	193,000
Noncontrolling Interest [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 329,000	$ 462,000

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	43.00%	39.00%
Customer X [Member] | Accounts Receivable [Member]
Credit concentration	25.00%	12.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration		18.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member] | Maximum [Member]
Credit concentration	10.00%
Customer Y [Member] | Accounts Receivable [Member]
Credit concentration	10.00%	31.00%
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration		10.00%
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member] | Maximum [Member]
Credit concentration	26.00%
Customer Z [Member] | Accounts Receivable [Member]
Credit concentration	11.00%	10.00%
Customer D [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	18.00%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Raw material	$ 14	$ 14
Finished goods	12	12
Total	$ 26	$ 26

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Non Plan [Member]
Risk free interest rate	2.65%	2.43%
Expected volatility	152.00%	252.00%
Expected dividend yield
Life in years (Year)	7 years	7 years
2018 Equity Incentive Plan [Member]
Risk free interest rate	2.65%
Expected volatility	152.00%
Expected dividend yield
Life in years (Year)	7 years

Note 3 - Lincoln Park Financi_2

Note 3 - Lincoln Park Financing (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Aug. 25, 2017
Proceeds from Issuance of Common Stock		$ 168,000
Lincoln Park Capital Fund, LLC [Member]
Stock Purchase Agreement, Maximum Amount of Common Stock			$ 10,000,000
Stock Issued During Period, Shares, New Issues		650,000
Proceeds from Issuance of Common Stock		$ 168,220

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)	Mar. 07, 2019	Feb. 05, 2019	Feb. 04, 2019	Jan. 31, 2019	Jan. 22, 2019	Jan. 14, 2019	Jan. 07, 2019	Jan. 03, 2019	Sep. 19, 2018	Mar. 01, 2018	Jan. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 28, 2019	Mar. 05, 2019	Jan. 06, 2019	Jan. 05, 2019	Dec. 31, 2018	Oct. 16, 2018	Dec. 31, 2017
Interest Expense, Debt, Total												$ 985,000	$ 832,000
Proceeds from Notes Payable, Total												170,000
Gain (Loss) on Extinguishment of Debt, Total												$ (184,000)
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 1	$ 1					$ 1		$ 1
Common Stock, Shares Authorized												400,000,000						400,000,000
Lincoln Park Capital Fund, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				50,000			250,000				50,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25			$ 0.25				$ 0.25
Class of Warrant or Right, Expiration Term							5 years				5 years
Conversion of Principal Amount into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued												1,638,479
Conversion of Accrued Interest into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued												40,769
Convertible Notes Payable [Member]
Short-term Debt, Total												$ 2,072,000
Convertible Notes Payable [Member] | Tangiers Global [Member]
Debt Instrument, Face Amount		$ 330,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price				75.00%							75.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date				25 days
Debt Instrument, Convertible, Default Penalty				22.00%							22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature				$ 185,000
Short-term Debt, Total												554,000
Proceeds from Convertible Debt	$ 150,000	300,000
Debt Instrument, Convertible, Interest Rate on Remaining Principal				12.00%							12.00%
Debt Instrument, Convertible, Aggregate Principal Amount				$ 495,000							$ 495,000
Debt Instrument, Unamortized Discount, Total		$ 10
Debt Instrument, Convertible, Days to Prepay Following Effective Date				180 days
Debt Instrument, Default, Percentage of Principal				25.00%							25.00%
Common Stock, Shares Authorized				3,000,000							3,000,000
Convertible Notes Payable [Member] | Tangiers Global [Member] | Tangiers Global Convertible Note, Prepayment Period First 90 Days [Member]
Debt Instrument, Convertible, Prepayment Penalty				25.00%							25.00%
Convertible Notes Payable [Member] | Tangiers Global [Member] | Tangiers Global Convertible Note Prepayment Period Second 90 Days [Member]
Debt Instrument, Convertible, Prepayment Penalty				30.00%							30.00%
Notes Payable, Maturing January 5, 2019 [Member]
Proceeds from Notes Payable, Total									$ 400,000
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Debt Instrument, Face Amount								$ 400,000
Debt Instrument, Period of Extension								60 days
Debt Instrument Extension Option Increase In Principal Percentage								10.00%
Debt Instrument, Face Value, After Increase from Maturity Date Extension																	$ 440,000
Debt Instrument, Interest Rate After Maturity Date Extension															18.00%
Notes Payable, Maturing January 5, 2019 [Member] | Vernal Bay Investments, LLC [Member]
Debt Instrument, Face Amount									$ 280,000
Notes Payable, Maturing January 5, 2019 [Member] | Chappy Bean, LLC [Member]
Debt Instrument, Face Amount									$ 120,000
Triton Fund Investment [Member]
Debt Instrument, Interest Rate, Stated Percentage																			5.00%
Debt Instrument, Face Amount																			$ 300,000
Bridge Loan																			225,000
Discount On Convertible Note Payable																			$ 75,000
Vista Capital 2017 Note [Member]
Debt Instrument Extension Option Increase In Principal Percentage										10.00%
Gain (Loss) on Extinguishment of Debt, Total												(38,000)
Debt Conversion, Original Debt, Amount												$ 225,000
Debt Conversion, Converted Instrument, Shares Issued												1,679,248
Vista Capital 2017 Note [Member] | Convertible Notes Payable [Member]
Short-term Debt, Total												$ 420,000
Vista Capital 2017 Note [Member] | Convertible Notes Payable [Member] | Vista Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Debt Instrument, Face Value, After Increase from Maturity Date Extension							$ 605,100							$ 420,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price							80.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date							25 days
Debt Instrument, Convertible, Prepayment Penalty							15.00%									20.00%
Debt Instrument, Convertible, Default Penalty							25.00%									30.00%
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 487,000
Vista Capital 2019 Note [Member] | Convertible Notes Payable [Member] | Vista Capital [Member]
Debt Instrument, Interest Rate, Stated Percentage							12.00%
Debt Instrument, Face Amount							$ 330,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price							65.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date							25 days
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 300,000
Proceeds from Convertible Debt							$ 300,000
Common Stock, Limit on Ownership Interest, Percent							4.99%
Debt Instrument, Convertible, Number of Business Days Notice of Prepayment							10 days
Debt Instrument, Convertible, Outstanding Balance Including Prepayment Penalty, Percent							120.00%
OID Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Percentage of Principal Value of Note, Numerator Value of Calculation			75.00%
Class of Warrant or Right, Denominator Value of Calculation			$ 0.25
OID Note [Member] | Convertible Notes Payable [Member]
Proceeds from Notes Payable, Total			$ 100,000		$ 20,000	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Debt Instrument, Face Amount			$ 125,000		$ 25,000	$ 62,500						$ 212,500
Debt Instrument, Unamortized Discount, Total			42,500
Original Issue Discount, Percentage												25.00%
Debt Instrument, Convertible, Conversion Price												$ 0.25
Amount of Qualifying Offering Needed to Trigger Note Prepayment			$ 3,500,000

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($)		Mar. 31, 2019	Dec. 31, 2018
Notes payable		$ 490,000	$ 400,000
Convertible Notes Payable, Current		2,072,000	1,365,000
Total current liabilities		2,992,000	2,195,000
Long-term Debt, Excluding Current Maturities, Total		1,242,000	1,292,000
Total		4,234,000	3,487,000
Notes Payable, Maturing June 6, 2019 [Member]
Notes payable		440,000	400,000
Convertible Notes Payable, Current		440,000
Note Payable, Maturing March 8, 2023 [Member]
Notes payable		50,000
Line of Credit, Maturing September 1, 2019 [Member]
Long-term Line of Credit, Total	[1]	430,000	430,000
Convertible Notes Maturing on December 31, 2019 [Member]
Convertible Notes Payable, Current		75,000	75,000
Convertible Notes Maturing January 11, 2019 [Member]
Convertible Notes Payable, Current			300,000
Convertible Note, Maturing on July 15, 2019 [Member]
Convertible Notes Payable, Current	[1]	420,000	550,000
Convertible Notes, Maturing July 20, 2019 [Member]
Convertible Notes Payable, Current	[2]	440,000	440,000
Convertible Note, Maturing October 7, 2019 [Member]
Convertible Notes Payable, Current		370,000
Convertible Note, Maturing November 5, 2019 [Member]
Convertible Notes Payable, Current		554,000
Convertible Nine Month Notes, due October, November 2019 [Member]
Convertible Notes Payable, Current		213,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total		1,007,000	1,007,000
Convertible Notes, Maturing on June 20, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total		25,000	25,000
Convertible Notes, Maturing April 20, 2021 [Member]
Long-term Debt, Excluding Current Maturities, Total	[1]	100,000	100,000
Convertible Notes, Mature June 15, 2021 [Member]
Long-term Debt, Excluding Current Maturities, Total		110,000	110,000
Convertible Note, Maturing On March 8, 2023 [Member]
Long-term Debt, Excluding Current Maturities, Total			$ 50,000
[1]	See Note 14 "Subsequent Events"
[2]	These notes are convertible at our option at maturity.

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Mar. 31, 2019	Mar. 29, 2019	Jan. 16, 2019	Jun. 22, 2018	Sep. 07, 2017	Mar. 31, 2019	Mar. 31, 2018
Stock Issued During Period, Value, Issued for Services						$ 206,000	$ 197,000
Share Price			$ 0.22
2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	$ 0.16					$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				40,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						890,280
The 2007 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	0.16					$ 0.16
Non Plan [Member]
Shares Issued, Price Per Share	$ 0.16					$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						731,250	619,435
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense						$ 352,000	$ 320,000
Maximum [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Officer [Member]
Stock Issued During Period, Shares, Issued for Services	323,030	579,996
Shares Issued, Price Per Share	$ 0.26	$ 0.16				$ 0.26
Stock Issued During Period, Value, Issued for Services	$ 84,000	$ 93,000
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services						788,907	1,008,478
Stock Issued During Period, Value, Issued for Services						$ 138,000	$ 277,000
Consultants [Member] | Minimum [Member]
Shares Issued, Price Per Share	$ 0.16					$ 0.16	$ 0.25
Consultants [Member] | Maximum [Member]
Shares Issued, Price Per Share	0.23					0.23	$ 0.41
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	0.22					$ 0.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						300,000
Chief Financial Officer [Member] | Equity Incentive Plan 2007 [Member]
Share-based Payment Arrangement, Expense						$ 67,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Remaining Number of Shares to Vest Each Month			25,000
Chief Financial Officer [Member] | Selling, General and Administrative Expenses [Member] | Equity Incentive Plan 2007 [Member]
Share-based Payment Arrangement, Expense						$ 17,000
Employees [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						168,404
Employees [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	0.16					$ 0.16
Employees [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	0.25					$ 0.25
Employees and CFO [Member] | Selling, General and Administrative Expenses [Member] | 2018 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense						$ 36,000
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share	0.16					$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						421,876
Board Of Directors [Member] | Selling, General and Administrative Expenses [Member] | 2018 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense						$ 68,000
Vendors [Member] | Non Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						731,250
Vendors [Member] | Selling, General and Administrative Expenses [Member] | Non Plan [Member]
Share-based Payment Arrangement, Expense						$ 139,000
Vendors [Member] | Minimum [Member] | Non Plan [Member]
Shares Issued, Price Per Share	0.16					$ 0.16
Vendors [Member] | Maximum [Member] | Non Plan [Member]
Shares Issued, Price Per Share	$ 0.25					$ 0.25
Board of Directors and Vendors [Member] | Non Plan [Member]
Stock Issued During Period, Value, Issued for Services							$ 158,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						619,435
Board of Directors and Vendors [Member] | Minimum [Member] | Non Plan [Member]
Shares Issued, Price Per Share							$ 0.26
Board of Directors and Vendors [Member] | Maximum [Member] | Non Plan [Member]
Shares Issued, Price Per Share							$ 0.28

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details) - USD ($)		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		1,318,517
Weighted average price per share, balance (in dollars per share)		$ 0.30		$ 0.25	$ 0.30
Aggregate intrinsic value, balance	[1]
Options outstanding, granted (in shares)		890,280
Weighted average price per share, granted (in dollars per share)		$ 0.19
Options outstanding, balance (in shares)		2,208,797
Weighted average price per share, balance (in dollars per share)		$ 0.30
Weighted average price per share, balance (in dollars per share)		0.25
2018 Equity Incentive Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)		0.22
Exercise price per share, granted (in dollars per share)		0.16
Exercise price per share, balance (in dollars per share)		0.16
2018 Equity Incentive Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)		0.43
Exercise price per share, granted (in dollars per share)		0.22
Exercise price per share, balance (in dollars per share)		$ 0.43
Equity Incentive Plan 2007 [Member]
Options outstanding, balance (in shares)		9,691,586	9,831,586
Weighted average price per share, balance (in dollars per share)		$ 0.43	$ 0.44	$ 0.43	$ 0.43	$ 0.43
Aggregate intrinsic value, balance	[1]
Options outstanding, balance (in shares)		9,661,586	9,781,586
Weighted average price per share, balance (in dollars per share)		$ 0.43	$ 0.44
Options outstanding, expired (in shares)		(30,000)	(50,000)
Exercise price per share, expired (in dollars per share)			$ 1.89
Weighted average price per share, expired (in dollars per share)		$ 0.50	0.91
Weighted average price per share, balance (in dollars per share)		0.43	0.43
Equity Incentive Plan 2007 [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)		0.23	0.23
Exercise price per share, balance (in dollars per share)		0.23	0.23
Exercise price per share, expired (in dollars per share)		0.38
Equity Incentive Plan 2007 [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)		0.94	1.89
Exercise price per share, balance (in dollars per share)		1.65	$ 1.65
Exercise price per share, expired (in dollars per share)		$ 0.70
Non Plan [Member]
Options outstanding, balance (in shares)		19,319,496	20,018,408
Weighted average price per share, balance (in dollars per share)		$ 0.43	$ 0.51	$ 0.42	$ 0.43	$ 0.45
Aggregate intrinsic value, balance	[1]
Options outstanding, granted (in shares)		731,250	619,435
Weighted average price per share, granted (in dollars per share)		$ 0.19	$ 0.26
Options outstanding, balance (in shares)		20,050,746	18,237,843
Weighted average price per share, balance (in dollars per share)		$ 0.43	$ 0.51
Options outstanding, expired (in shares)			(2,400,000)
Exercise price per share, expired (in dollars per share)			$ 0.99
Weighted average price per share, expired (in dollars per share)			0.99
Weighted average price per share, balance (in dollars per share)		0.42	0.45
Non Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)		0.23	0.25
Exercise price per share, granted (in dollars per share)		0.16	0.26
Exercise price per share, balance (in dollars per share)		0.25	0.25
Non Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)		1	1
Exercise price per share, granted (in dollars per share)		0.25	0.28
Exercise price per share, balance (in dollars per share)		$ 1	$ 1
[1]	Aggregate intrinsic value based on closing common stock price of $0.16 at March 31, 2019.

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)	Dec. 30, 2016	Jul. 08, 2016	Mar. 31, 2019	Mar. 31, 2018	Mar. 05, 2019	Mar. 04, 2019	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1	$ 1				$ 1	$ 1
Gain (Loss) on Extinguishment of Debt, Total			$ (184,000)
Class of Warrant or Right, Issued During Period			3,861,041	2,611,513
Deemed Dividends			$ 342,000	$ 297,000
Warrants Issued as Part of Debt Extension [Member]
Gain (Loss) on Extinguishment of Debt, Total			$ (56,000)
Warrants Issued Concurrently with the Nine-month Note Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			637,500
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Warrants and Rights Outstanding, Term			5 years
Discount On Convertible Note Payable			$ 89,000
Class of Warrant or Right, Percentage of Principal Value of Note, Numerator Value of Calculation			75.00%
Class of Warrant or Right, Denominator Value of Calculation			$ 0.25
Warrants Issued Concurrently With One Year Convertible Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75	$ 0.65	$ 0.12
Class of Warrant or Right, Issued During Period	400,000	400,000
Increase (Decrease) Warrants Available for Exercise			2,426,666
Deemed Dividends			$ 342,000
Vernal Bay Investments, LLC [Member] | Warrants Issued as Part of Debt Extension [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,734,375	1,387,500
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.20	$ 0.25
Maximum Investment Amount under Warrant					$ 346,875
Chappy Bean, LLC [Member] | Warrants Issued as Part of Debt Extension [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					750,000	600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.20
Lincoln Park Capital Fund, LLC [Member] | Warrants Issued as Consent for Variable Rate Date [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.25
Warrants and Rights Outstanding, Term							5 years
Discount On Convertible Note Payable							$ 54,000

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance, outstanding (in shares)	26,872,430	22,104,817
Balance, outstanding, price range (in dollars per share)	$ 1	$ 1
Issued (in shares)	3,861,041	2,611,513
Issued, price range (in dollars per share)	$ 0.25	$ 0.48
Balance, outstanding (in shares)	30,733,471	24,716,330
Balance, outstanding, price range (in dollars per share)	$ 1	$ 1
Balance, weighted average price per share (in dollars per share)
Minimum [Member]
Balance, outstanding, price range (in dollars per share)	0.25	0.125
Issued, price range (in dollars per share)	0.16	0.25
Balance, outstanding, price range (in dollars per share)	0.20	0.125
Maximum [Member]
Balance, outstanding, price range (in dollars per share)	0.42	0.45
Issued, price range (in dollars per share)	0.24	0.35
Balance, outstanding, price range (in dollars per share)	$ 0.40	$ 0.44

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Risk free interest rate		2.54%
Expected volatility		252.00%
Minimum [Member]
Risk free interest rate	2.18%
Expected volatility	86.00%
Expected life (Year)	2 years	5 years
Maximum [Member]
Risk free interest rate	2.62%
Expected volatility	110.00%
Expected life (Year)	5 years	10 years

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts payable and accrued expense	$ 370	$ 302
Accrued interest	151	122
Accrued payroll	110	77
Total accounts payable and accrued expenses	$ 631	$ 501

Note 8 - Noncontrolling Inter_3

Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($)	Sep. 26, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Proceeds from Issuance of Common Stock			$ 168,000
Long-term Debt, Excluding Current Maturities, Total		$ 1,242,000		$ 1,292,000
Preferred Stock, Shares Outstanding, Ending Balance		0		0
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total		$ 1,007,000		$ 1,007,000
Clyra [Member]
Proceeds from Issuance of Common Stock		$ 110,000
Shares Issued, Price Per Share		$ 550
Clyra Medical Technology Inc [Member] | Sanatio [Member]
Common Stock, Shares, Outstanding, Ending Balance		1,690
Preferred Stock, Dividend Rate, Percentage		8.00%
Preferred Shares Dividend, Period		5 years
Dividends Payable, Current		$ 200,000
Clyra Medical Technology Inc [Member] | Sanatio [Member] | Preferred Class A [Member]
Preferred Stock, Shares Outstanding, Ending Balance		9,830
Scion Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	21,000
Business Combination, Consideration Transferred, Liabilities Incurred	$ 1,250,000
Business Acquisition, Base Capital Requirement for Escrow Release	1,000,000
Business Acquisition, Gross Revenue, Tranche One	100,000
Business Acquisition, Gross Revenue, Tranche Two	100,000
Business Acquisition, Gross Revenue, Tranche Three	500,000
Business Acquisition, Gross Revenue, Tranche Five	2,000,000
Scion Acquisition [Member] | Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total		$ 1,007,000
Scion Acquisition [Member] | Clyra [Member]
Debt Instrument, Face Amount	$ 1,250,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Percent of Investment Proceeds	25.00%
Debt Instrument, Extension Period	1 year
Debt Instrument, Term	1 year 180 days
Debt Instrument, Percent of Gross Revenue	5.00%
Scion Acquisition [Member] | Clyra Medical Technology Inc [Member]
Proceeds from Issuance of Common Stock		$ 1,110,000
Shares Issued, Price Per Share		$ 200
Scion Acquisition [Member] | Clyra Acquisition, Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	10,000	15,500		15,500
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,142,858

Note 8 - Noncontrolling Inter_4

Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details) - Clyra Medical Technology Inc [Member]	Mar. 31, 2019shares
Shares, Outstanding (in shares)	66,845
Biolargo [Member]
Shares, Outstanding (in shares)	28,053
Percent	42.00%
Sanatio [Member]
Shares, Outstanding (in shares)	11,520	[1]
Percent	17.40%	[1]
Scion Solutions [Member]
Shares, Outstanding (in shares)	15,500	[2]
Percent	23.40%	[2]
Other [Member]
Shares, Outstanding (in shares)	11,772
Percent	17.20%
[1]	Includes 9,830 Series A Preferred shares (see below), and 1,690 common shares.
[2]	Does not include an additional 15,500 shares held in escrow subject to performance metrics.

Note 9 - BioLargo Engineering_2

Note 9 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) shares in Millions	1 Months Ended
	Sep. 30, 2017shares
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Deferred Compensation Arrangement with Individual, Requisite Service Period	5 years
Potential Ownership Percentage of Subsidiary Held by Subsidiary Employees Based on Performance	30.00%
Incentive Issuance Stipulations for Subsidiary Employees, Accounts Receivable Collected by Year One of Operation	90.00%
Incentive Issuance Stipulations for Subsidiary Employees, Profit Earned in Year One of Operation	10.00%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%
Leased Property in Knoxville, Tennessee for BioLargo Engineering, Science & Technologies, LLC [Member]
Lessee, Operating Lease, Term of Contract	3 years

Note 10 - Business Segment In_3

Note 10 - Business Segment Information (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Number of Operating Segments	4
Payments of Distributions to Affiliates			$ 417,000
Revenue from Contract with Customer, Including Assessed Tax	$ 364,000	$ 364,000	1,364,000
Odor-No-More [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 301,000	$ 224,000	$ 1,000,000	$ 500,000

Note 10 - Business Segment In_4

Note 10 - Business Segment Information - Segment Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 364,000	$ 364,000	$ 1,364,000
Intersegment revenue
Operating loss	(1,662,000)	(1,602,000)
Grant income	82,000	5,000
Interest expense	(985,000)	(832,000)
Depreciation	(16,000)	(10,000)
Research and development	(426,000)	(522,000)
Loss on extinguishment	(184,000)
Net loss	(2,749,000)	(2,429,000)
Tangible assets	1,503,000		1,292,000
Intangible assets	1,893,000		1,893,000
Consolidation, Eliminations [Member]
Revenue	(120,000)	(120,000)
Intersegment revenue
Operating loss
Grant income
Interest expense
Depreciation
Research and development	126,000	150,000
Loss on extinguishment
Net loss
Tangible assets	(6,000)		(6,000)
Intangible assets
Biolargo [Member]
Revenue
Intersegment revenue
Operating loss	(948,000)	(1,093,000)
Grant income
Interest expense	(632,000)	(830,000)
Depreciation
Research and development	(172,000)	(343,000)
Loss on extinguishment	(184,000)
Net loss	(2,105,000)	(1,924,000)
Tangible assets	673,000		353,000
Intangible assets	1,893,000		1,893,000
Odor-No-More [Member]
Revenue	301,000	224,000	1,000,000	$ 500,000
Intersegment revenue
Operating loss	(90,000)	(109,000)
Grant income
Interest expense
Depreciation	(4,000)	(4,000)
Research and development
Loss on extinguishment
Net loss	(90,000)	(109,000)
Tangible assets	182,000		220,000
Intangible assets
Clyra [Member]
Revenue
Intersegment revenue
Operating loss	(287,000)	(199,000)
Grant income
Interest expense	(12,000)
Depreciation
Research and development	(49,000)	(87,000)
Loss on extinguishment
Net loss	(299,000)	(199,000)
Tangible assets	277,000		462,000
Intangible assets
BLEST [Member]
Revenue	183,000	189,000
Intersegment revenue	(120,000)	(150,000)
Operating loss	(110,000)	(45,000)
Grant income
Interest expense		(2,000)
Depreciation	(12,000)	(6,000)
Research and development	(122,000)	(100,000)
Loss on extinguishment
Net loss	(110,000)	(46,000)
Tangible assets	329,000		230,000
Intangible assets
BioLargo Water [Member]
Revenue
Intersegment revenue
Operating loss	(227,000)	(156,000)
Grant income	82,000	5,000
Interest expense
Depreciation
Research and development	(209,000)	(142,000)
Loss on extinguishment
Net loss	(145,000)	$ (151,000)
Tangible assets	48,000		33,000
Intangible assets

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	May 02, 2017	Mar. 31, 2019	Mar. 31, 2018
Operating Leases, Rent Expense, Total		$ 51,000	$ 49,000
Lessee, Operating Lease, Renewal Term		4 years
Lessee, Operating Lease, Discount Rate		18.00%
Consulting Services, Monthly Payment		$ 23,000
Consulting Services, Period of Services		4 years
Contractual Obligation, Total		$ 1,100,000
President and Chief Executive Officer [Member]
Employment Agreement, Annual Base Compensation	$ 289,000
Employment Agreement, Option, Number of Shares, Expected to Grant	3,731,322
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Employment Agreement, Common Stock, Expect to Grant, Subject to Lock-Up Agreement	1,500,000
Employment Agreement, Lock-up Agreement, Successful Commercialization, Minimum Cash Receipt	$ 3,000,000
Employment Agreement, Lock-up Agreement, Minimum Revenue Recognized	$ 3,000,000
Employment Agreement, Term	5 years
President and Chief Executive Officer [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.45

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Convertible Notes Payable [Member] - USD ($)	May 14, 2019	Apr. 18, 2019
Subsequent Event [Member] | Convertible Note to Crossover Capital Fund I, LP [Member]
Debt Instrument, Face Amount	$ 110,000
Original Issue Discount, Percentage	10.00%
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price	70.00%
Proceeds from Short-term Debt, Total	$ 95,000
Payments of Debt Issuance Costs	$ 5,000
Debt Instrument, Term	270 days
Debt Instrument, Repayment Period	180 days
Debt Instrument, Convertible, Prepayment Penalty, First 30 Days	5.00%
Debt Instrument, Convertible, Prepayment Penalty, Last 30 Days	30.00%
Debt Instrument, Convertible, Default Penalty	24.00%
Bellridge Capital, LP [Member] | Forecast [Member]
Debt Instrument, Convertible, Interest Rate on Remaining Principal		10.00%
Additional Proceeds From Convertible Debt		$ 400,000
Bellridge Capital, LP [Member] | Subsequent Event [Member]
Proceeds from Convertible Debt		$ 188,000
Debt Instrument, Convertible, Interest Rate on Remaining Principal		10.00%
Debt Instrument, Face Amount		$ 220,000
Original Issue Discount, Percentage		10.00%
Debt Instrument, Fee Amount		$ 10,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price		70.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date		25 days
Bellridge Capital, LP [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Default, Interest Rate		24.00%
Bellridge Capital, LP [Member] | Subsequent Event [Member] | Convertible Note, Prepayment Period, First 90 Days [Member]
Debt Instrument, Convertible, Prepayment Penalty		125.00%
Bellridge Capital, LP [Member] | Subsequent Event [Member] | Convertible Note Prepayment Period, Second 90 Days [Member]
Debt Instrument, Convertible, Prepayment Penalty		130.00%